Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Survival in patients with pancreatic cancer remains low

Treatment factors are related to survival time in pancreatic cancer, although there is racial disparity in therapies, reports September's American Journal of Surgery.

News image

fiogf49gjkf04

Dr Mohamad Eloubeidi and investigators performed a population-based study of patients from the deep South of the United States.

The investigative team evaluated the survival rate of patients with pancreatic cancer.

The team analyzed prognostic factors influencing pancreatic cancer survival using the Alabama Statewide Cancer Registry.

The investigators determined whether race/ethnicity is an independent determinant of outcomes in patients with pancreatic cancer.

The team included eligible participants diagnosed with pancreatic cancer from 1996 to 2000 and reported to the Alabama Statewide Cancer Registry.

Survival time was calculated from time of diagnosis to death for pancreatic cancer deaths.

The team also calculated survival time from the time of diagnosis to date of last contact or death from other causes for censored participants.

Risk factors associated with survival were assessed with the Kaplan-Meier survival method and the log-rank test.

The median survival time for all patients was less than 5 months
American Journal of Surgery

Demographic, tumor, and treatment variables were assessed using the Cox proportional hazards model.

The investigators evaluated 2230 patients, whose median age at diagnosis was 71 years with a male to female ratio of approximately 1 to 1.

Of these patients, 73% were white, and 27% were black.

The distribution by stage was 13% localized disease, 30% regional, 35% distant, and 23% unstaged.

The median survival time for all patients was less than 5 months.

The investigators noted that patients who underwent surgical treatment were less likely to die of pancreatic cancer.

Similarly, patients who underwent either chemotherapy or radiation therapy had improved survival rates.

Across all stages, the team observed that black patients were significantly less likely to receive chemotherapy compared with white patients.

These patients were less likely to receive surgical intervention.

When examining patients who were offered their therapy of choice but refused, the team found that a greater proportion of black patients refused therapies.

For chemotherapy, 4% of black patients refused therapy versus 2% of white patients.

The team noted that for radiation, and 9% of black patients refused therapy versus 3% of white patients.

The Cox proportional hazard model showed no effect of race on overall survival time while controlling for stage at presentation.

In addition, the investigators observed no effect of race on survival controlling for type of therapy received, age at diagnosis, and site of primary tumor.

Dr Eloubeidi's team concluded, “Survival in patients with pancreatic cancer remains dismal.”

“Tumor characteristics and treatment factors are related directly to survival time in patients with pancreatic cancer.”

“Black patients were less likely to receive therapy but also were more likely to refuse the indicated therapy.”

“Factors leading to racial disparity in the treatment of pancreatic cancer warrant further investigation.”

Am J Surg 2006: 192(3): 322-9
29 August 2006

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us